YS Biopharma (YSB) Stock Forecast & Price Target

YS Biopharma - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Buy

Based on 1 Analyst Ratings

Sell
0

Hold
0

Buy
1

Consensus Price Target

$5.25
N/A

Get the Latest News and Ratings for YSB and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for YS Biopharma and its competitors.

YSB Analyst Ratings Over Time

Type	Current Forecast 10/19/23 to 10/18/24	1 Month Ago 9/19/23 to 9/18/24	3 Months Ago 7/21/23 to 7/20/24	1 Year Ago 10/19/22 to 10/19/23
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	N/A
Buy	1 Buy rating(s)	1 Buy rating(s)	1 Buy rating(s)	N/A
Hold	0 Hold rating(s)	0 Hold rating(s)	0 Hold rating(s)	N/A
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	N/A
Consensus Price Target	$5.25	$5.25	$5.25	N/A
Forecasted Upside	N/A	563.63% Upside	971.65% Upside	N/A
Consensus Rating	Buy	Buy	Buy	N/A

Watch this before it gets removed (Ad)

If you missed it, my emergency election broadcast is now available - but will be removed on Monday at midnight.

Click here to watch it now.

YSB Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

YSB Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

YS Biopharma Stock vs. The Competition

Type	YS Biopharma	Medical Companies	S&P 500
Consensus Rating Score	3.00	2.79	2.50
Consensus Rating	Buy	Moderate Buy	Hold
Predicted Upside	N/A	12,964.24% Upside	6.38% Upside
News Sentiment Rating	Neutral News See Recent YSB News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date	Details
11/13/2023	Noble Financial 5 of 5 stars		Initiated Coverage	Outperform	$5.25	+797.58%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Friday at 01:21 AM ET.

YSB Forecast - Frequently Asked Questions

: According to the research reports of 1 Wall Street equities research analysts, the average twelve-month stock price forecast for YS Biopharma is $5.25, with a high forecast of $5.25 and a low forecast of $5.25.
: 1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for YS Biopharma in the last twelve months. There is currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" YSB shares.
: According to analysts, YS Biopharma's stock has a predicted upside of ∞ based on their 12-month stock forecasts.
: Analysts like YS Biopharma more than other "medical" companies. The consensus rating for YS Biopharma is Buy while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how YSB compares to other companies.